Histological definition of a lymph node - based on a survey among Danish pathologists

Size: px
Start display at page:

Download "Histological definition of a lymph node - based on a survey among Danish pathologists"

Transcription

1 1 O1-1 Histological definition of a lymph node - based on a survey among Danish pathologists Agnete Riisgaard Sørensen (1), Astrid Petersen (1). (1)Department of Pathology, Aalborg University Hospital, Aalborg, Denmark. O1-2 Processing times for gastrointestinal biopsies with suspected malignancy can be reduced by a simple intervention Tina Prangsgaard (1+2) Ulla Engel (1). (1) Hvidovre University Hospital, Department of Pathology, Hvidovre, Denmark, (2) Department of Pathology, Herlev Hospital, Denmark O1-3 Validation of automated image analysis on HER2 expression in breast cancer Henrik Holm Rossing (1), Martin Kristensson (2), Maj-Lis Møller Talman (1), Ben Vainer (1). (1) Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. (2) Visiopharm, Hoersholm, Denmark. O1-4 The influence of preoperative chemo-radiotherapy on lymph node yield, N-status and survival in rectal cancer Results from a nationwide cohort study Jakob Lykke M.D (1)., Per Jess M.D., DMSci(2) and Ole Roikjaer M.D(2) On behalf of the Danish Colorectal Cancer Group. (1)Department of Surgery, Slagelse Hospital, University of Copenhagen, Faelledvej 1, 4200 Slagelse, Denmark. (2)Department of Surgery, Roskilde Hospital, University of Copenhagen, Koegevej 7-13, Roskilde, Denmark. O1-5 Repeated biopsies in prostate cancer patients on active surveillance: clinical implications of interobserver variation in histopathological assessment Frederik B. Thomsen(1), Niels Marcussen(2), Kasper Drimer Berg(1), Klaus Brasso(1), Ib Jarle Christensen(3), Ben Vainer(4), Peter Iversen(1) 1) Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen 2) Department of Clinical Pathology, Odense University Hospital, University of Odense. O1-6 Post-operative multi-disciplinary team meeting have a positive effect on the surgical quality in colon cancer Ditte Louise E. Munkedal (1) Nicholas P. West (2) Lene H. Iversen (1) Rikke Hagemann-Madsen (3) Philip Quirke (2) Søren Laurberg (1). (1)Department of Surgery P, Aarhus University Hospital, Aarhus, Denmark, (2)Pathology, Anatomy and Tumour Biology, Leeds Institute of Cancer and Pathology, School of Medicine, University of Leeds, Leeds,

2 2 United Kingdom, (3)Pathology Department, Aarhus University. O1-7 Utility of anti-phosphohistone H3 (PHH3) immunreactivity to determine mitotic rate in gastrointestinal stromal tumours an interobserver variability study Iordache A, Jensen MB, Woller NC, Langhoff JL, Toxværd A, Riis LB (1)Department of Pathology, Herlev Hospital O1-8 Influence of reduction formalin fixation time on the quality of histomorphology and lymph node retrieval in Colorectal Cancer Ban A. Abdulwahab (1), Ulla Engel (1), Mahin Mohammadi (1). (1) Hvidovre University Hospital, Department of Pathology, Hvidovre, Denmark O1-9 Early colorectal cancer mirna profile Anne-Marie Kanstrup Fiehn (1), Gro Linno Willemoe (1), David Hebbelstrup Jensen (2), Ben Vainer (1) (1)Department of Pathology, Rigshospitalet, Copenhagen, Denmark, (2)Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark O2-1 The prevalence of HPV in a screening population of 2965 women aged years in Southern Jutland and Fyn. Comparison of the Cobas HPV Assay, Roche and the Hybrid Capture 2 Test, Qiagen Dorthe Ørnskov (1) Marianne Waldstrøm (1,2) (1)Department of Pathology, Vejle Hospital, Denmark (2) Institute of Regional Health Research, University of Southern Denmark. O2-2 Is rapid rescreening of cervical cytology samples worth the effort? Dorthe Ejersbo (1), Marianne Waldstrøm(1,2) (1)Department of Pathology, Vejle Hospital, Denmark (2) Institute of Regional Health Research, University of Southern Denmark. O2-3 Comparison of four HPV assays in a primary screening population on women 30 years of age Rebolj M (1), Ejegod D (2,3), Preisler S (2,3), Rygaard C (2), Lynge E (1), Bonde J (2,3) (1)University of Copenhagen, Department of Public Health, Copenhagen, Denmark, (2)Hvidovre University Hospital, Department of Pathology, Hvidovre, Denmark, (3)Hvidovre University Hospital, Clinical Research Centre, Hvidovre, Denmark. O2-4 Detection of high-grade CIN by four HPV assays in women with abnormal cytology Bonde J (1,2), Rebolj M (3), Preisler S (1,2), Ejegod D (1), Lynge E (3), Rygaard C (1)

3 3 (1)Hvidovre University Hospital, Department of Pathology, Hvidovre, Denmark, (2)Hvidovre University Hospital, Clinical Research Center, Hvidovre, Denmark, (3)University of Copenhagen, Department of Public Health, Copenhagen, Denmark. O2-5 The Aptima HPV mrna Assay is as sensitive but more specific than the Linear Array HPV DNA Test for post-treatment surveillance Marianne Waldstrøm (1,2), Dorthe Ørnskov (1) (1)Department of Pathology, Vejle Hospital, Denmark (2) Institute of Regional Health Research, University of Southern Denmark. O2-6 HPV test by use of RNA method in cervical cytology Sofie Hansen (1), Susanne Merete Nielsen (1), Karsten Nielsen (1) (1)Department of Pathology, Naestved Hospital and Institute of Regional Health Research, University of Southern Denmark O2-7 HPV-findings in women + 60 years old Susanne M. Nielsen (1), Karsten Nielsen (1,2) (1) Department of Pathology, Naestved Hospital, (2)Institute of Regional Health Research, Odense O2-8 Detection of HPV in anal cancer and low rectal cancer Jan Lindebjerg (1), Marianne Waldstrøm (1,2), Dorthe Ørnskov (1) (1)Department of Pathology, Vejle Hospital, Denmark (2) Institute of Regional Health Research, University of Southern Denmark. O2-9 A study on Interobserver Reproducibility in Diagnosis of Endometrial Carcinoma BH Winberg(1), VR Skovlund(1,) E Høgdall (1), IJ Christensen (2), M Lidang(1) (1)Dept. Pathology, Herlev Hospital, Denmark, (2)Finsen Laboratory, Copenhagen, Denmark. Tissue Micro Array in order to evaluate the improvement of the diagnosis of endometrial carcinoma. O3-1 c-kit expression in cutaneous melanoma Johanne Lade-Keller (1), Rikke Riber-Hansen (1), Christina Dahl (2), Per Guldberg (2), Henrik Schmidt (3) Stephen Hamilton-Dutoit (1), Torben Steiniche (1) (1)Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark, (2)Danish Cancer Society Research Center, Copenhagen, Denmark, (3)Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. O3-2

4 4 A stereological approach to immunohistochemical differentiation between Spitz nevi and malignant melanomas Suku MLH (1), Sørensen FB (2), Sørensen S (3), Pakkenberg B (3), Hastrup N (1), Henrik-Nielsen R (1), Gjerdrum LMR (1). (1)Department of Pathology, Rigshospitalet, Denmark (2)Department of Pathology, Vejle Sygehus, Denmark (3)Research Laboratory for Stereology and Neuroscience, Bispebjerg Hospital, Denmark. O3-3 Cell of origin as a possible predictive marker for response to treatment with R-CHOEP in young high-risk patients with DLBCL Mette Ø. Pedersen(1), Anne O. Gang (2), Tim S. Poulsen (1), Helle Knudsen (1), Anne F. Lauritzen (1), Signe L. Nielsen (1), Tobias W. Klausen (2), Michael Pedersen (2), Peter Brown (3), Peter Nørgaard (1), Shared first authorship (1)Department of Pathology, Herlev Hospital, Denmark, (2)Department of Haematology, Herlev Hospital, Denmark, (3)Department of Haematology, Rigshospitalet, Denmark. O3-4 Mutation frequencies of NOTCH1, SF3B1, MYD88, TP53 and POT1 in a cohort of CLL patients from the Region of Southern Denmark Louise Kristensen (1), Thomas Kielsgaard Kristensen (1), Cristina Royo (2), Niels Abildgaard (3), Elias Campo (2), Michael Boe Møller (1) (1)Department of Clinical Pathology, Odense University Hospital, (2)Anatomia Patólogica, Hospital Clinic, University of Barcelona, Spain, (3)Department of Haematology, Odense University Hospital. O3-5 Can EGFR-mutational status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung? Kim Hein Lindahl(1,3), Flemming Brandt Sørensen(1,2), Søren Peder Jonstrup(1), Karen Ege Olsen(3) & Siegfried Loeschke(1,4) (1)Department of Pathology, Vejle Hospital, Denmark, (2)Institute of Regional Health Research, University of Southern Denmark, (3)Department of Clinical Pathology, Odense University Hospital, Denmark, (4)Department of Clinical Pathology, Southern Jutland, Soenderborg, Denmark O3-6 Invasive Lobular Carcinoma of the Breast - Incidence of Multifocal and Bilateral Tumours during a 2-year period in Aarhus Helene Lintrup Pedersen (1) Vibeke Jensen (1) (1)Department of Pathology, Aarhus University Hospital, Denmark. O3-7 Automated estimation of Ki67 in 100 breast carcinomas Nina Woller (1) Tim Svenstrup Poulsen (1) Eva Balslev (1) Michael Friis Lippert (2)

5 5 (1)Department of Pathology, Herlev Hospital, (2) Visiopharm, Hoersholm, Denmark. O3-8 ER, PR, HER2, and Ki67 Index and Responsiveness to Adjuvant Tamoxifen in Postmenopausal High-Risk Breast Cancer Patients enrolled in the DBCG 77C trial Ann S. Knoop(1,2), Anne-Vibeke Lænkholm(7), Maj-Britt Jensen(3), Kirsten V. Nielsen(4), Jørn Andersen(5), Dorte Nielsen(6), Bent Ejlertsen(2,3)for the Danish Breast Cancer Cooperative Group (1)Department of Oncology, Odense University Hospital, Odense, (2)Department of Oncology, Rigshospitalet, Copenhagen, (3)Danish Breast Cancer Cooperative Group, Copenhagen (4)Dako Denmark A/S, Glostrup, (5)Department of Oncology, Aarhus University Hospital, Aarhus, (6)Department of Oncology, Herlev University Hospital, Herlev, (7)Department of Pathology, Slagelse Hospital, Slagelse O3-9 GATA3 as a potential marker for breast carcinoma Dorte Kjaer(1), Anja Brügmann(2), Søren Nielsen(3), Vibeke Jensen(1). (1)Department of Pathology, Aarhus University Hospital, Aarhus, Denmark, (2)Department of Pathology, Viborg Hospital, Viborg, Denmark, (3)Department of Pathology, Aalborg University Hospital, Aalborg, Denmark O4-1 Efficient microrna inhibition in a highly invasive orthotropic glioblastoma model Bo Halle (1-3) Eric Marcusson (4), Charlotte Aaberg-Jessen (1-3), Stine Skov Jensen (1-3), Morten Meyer (5), Mette Katrine Schulz (2) Claus Andersen (2) and Bjarne Winther Kristensen (1-3) (1)Department of Pathology, Odense University Hospital, Winsloewparken 15, 5000 Odense C, Denmark, (2)Department of Neurosurgery, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark, (3)Institute of Clinical Research, University of Southern Denmark, Winsloewparken 19, 5000 Odense C, Denmark, (4)Regulus Therapeutics, 3534 John Hopkins CT., Suite 210, San Diego, CA , USA, (5) Institute of Medical Biology, University of Southern Denmark, Winsloewparken 21, 5000 Odense C, Denmark O4-2 Pre-treatment diagnostic characteristics of 321 penile cancer patients - a national retrospective study from Denmark Jakobsen J.K.(1), Krarup K.P.(2), Sommer P.(2), Nerstrøm H.(2), Bakholdt V.(3), Sørensen J.A.(3), Olsen K.Ø.(4), Høyer S.(5),Toft B.G(6) Jensen J.B.(1) (01)Aarhus University Hospital, Dept. of Urology(1), Rigshospitalet, Copenhagen University Hospital, Dept. of Urology(2), Odense University Hospital, Dept. of Plastic Surgery(3), Odense University Hospital, Dept. of Urology(4), Aarhus University Hospital, Institute of Pathology(5), Rigshospitalet, Copenhagen University Hospital, Institute of Pathology(6) O4-3 Topoisomerase 1 and 2A gene copy number are elevated in colorectal cancer with proficient mismatch repair status Ida Marie Heeholm Sønderstrup(1), Sune Boris Nygård(2), Tim Svenstrup Poulsen(1), Dorte Linneman(1), Ib

6 6 Jarle Christensen(3), Nils Brünner(2), Peter Henrik Nørgaard(1), Lene Riis(1) (1)Department of Pathology, Herlev Hospital, (2)Section of Pathobiology, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, (3)Finsen Laboratory, Rigshospitalet and Biotech Research and Innovati. O4-4 ERG protein expression at diagnosis is associated with increased risk of disease progression during active surveillance Kasper Drimer Berg(1), Ben Vainer(2), Frederik Birkebæk Thomsen(1), M. Andreas Røder (1), Thomas Alexander Gerds(3), Birgitte Grønkær Toft(2), Klaus Brasso(1), Peter Iversen(1) (1)Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, (2) Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, (3)Department of Biostatistics, University of Copenhagen. O4-5 The Prostate cancer detection rate on the second prostate biopsy Zamel Hussain Zhaian (1), Karsten Nielsen (1) (1)Department of urology and Department of Pathology, Naestved Hospital, DK-4700 Naestved and Institute of Regional Health Research, University of Southern Denmark O4-6 Renal Cell Carcinoma the prognostic value of Fuhrman grades Sami Beji(1), Thomas Wagner Nielsen(2), Karsten Nielsen(2,3) (1) Department of Urology, Naestved Hospital, (2)Department of Pathology, Naestved Hospital, (3)Institute of Regional Health Research, University of Southern Denmark O4-7 Analysis of free circulating DNA in blood as a method for diagnosing and monitoring urinary bladder cancer patients Christina M. Dahmcke (1,2), Alastair B. Hansen (1), Per Guldberg (2) (1)Department of Pathology, Herlev Hospital, (2)CGL,The Danish Cancer Society O4-8 Evaluation of TOP1 gene copy number analysis in selecting prostate cancer patients for irinotecan treatment Jacob Bjerg Hansen(1), Sune Boris Nygård (2), Signe Lykke Nielsen(2), Nils Brünner(2), Anders Bjartell(3) and Ben Vainer (1). (1)Department of Pathology, Rigshospitalet, Copenhagen, (2)Section for Molecular Disease Biology, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, (3)Department of Clinical Sciences, Division of Urology, University of Lund, Sweden. O4-9

7 7 A comparison of the value of FNA and CNB in the clinical work up of cold thyroid nodules Vasilis Chatzikyriakos (1), Ida Maria Lisse (1), Katalin Kiss (1) (1) Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark P1-1 Case report: Small intestinal tophus mimicking tumour Katoch, Pragya (1), Trier-Mørch, Sara(2), Vyberg, Mogens(1) (1)Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark, (2)Department of Abdominal Surgery, Aalborg University Hospital, Aalborg, Denmark P1-2 Medullary carcinoma versus poorly differentiated adenocarcinoma of the colon can the undifferentiated be differentiated? Anne-Marie Kanstrup Fiehn (1), Ben Vainer (1), Anders Glenthøj (1), Gro Linno Willemoe(1). (1)Department of Pathology, Rigshospitalet, Copenhagen, Denmark. P1-3 Inflammatory fibroid polyp (IFP) with aberrant features Dorte Gybel-Brask (1), Tina Agander(1), Ulla Engel1, Susanne Holck (1) (1)Department of Pathology, Copenhagen University Hospital, Hvidovre P1-4 Cellulitis-like cutaneous metastasis as the first clinical sign of signet ring cell gastric carcinoma Annedorte Ries (1), Preben Løvgreen Nielsen (1) (1)Department of Pathology, Roskilde Hospital. P1-5 Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells: A case report Rouzbeh Salmani (1), Jane Preuss Hasselby (1), Birgitte H. Federspiel (1) (1)Department of Pathology, Copenhagen University Hospital, Rigshospitalet. P1-6 The challenges of molecular cancer mutation analysis: NRAS testing in colo-rectal cancer specimens Reza Rafiolsadat Serizawa(1), Delfina Fornari(1) Ulla Engel(1), Susanne Holck(1), Helle Pedersen(1), Jesper Bonde(1,2). (1)Department of Pathology, Copenhagen University Hospital Hvidovre, Denmark (2)Clinical Research Centre, Copenhagen UnO3iversity Hospital Hvidovre, Denmark. P1-7 IQGAP1 in rectal carcinomas before and after radiochemotherapy Susanne Holck (1), Emilie Hammer (2), Hans Jørgen Nielsen (2) and Lars-Inge Larsson (1) (1)Department of Pathology, Hvidovre Hospital, (2)Department of Surgery, Hvidovre Hospital.

8 8 P2-1 Autoimmune pancreatitis in Denmark: A single-centre study of 30 patients with histological, serological, imaging and clinical follow-up data Sönke Detlefsen(1), Michael Bau Mortensen(2), Anne-Sofie Cribe(3), Torsten Pless(2) and Ove B. Schaffalitzky de Muckadell(3). (1)Dept. of Pathology, Odense University Hospital, Odense, Denmark, (2)Dept. of Surgery, Odense University Hospital, Odense, Denmark, (3)Dept. of Medical Gastroenterology, Odense University Hospital, Odense, Denmark. P2-2 Extramammary Paget s disease in a mature cystic teratoma of the ovary May Murra (1), Aliaksandr Obukhau (1), Trine Tramm (1). (1) Department of Pathology, Randers Hospital, Denmark P2-3 Lipomatous tumours of the uterus: A report of 3 cases Thomas Wagner Nielsen (1), Karsten Nielsen (1+2) (1)Department of Pathology, Naestved Hospital, (2)Institute of Regional Health Research, Odense P2-4 Massive ovarian oedema in a 7-year old girl: a case report Gitte Hedegaard Jensen(1) Iben Birgit Gade Johnsen(1) (1)Department of Clinical Pathology, Odense University Hospital, Odense, Denmark P2-5 Adequacy in cervical cytology when changing from smear technique to liquid based technique Susanne Merete Nielsen (1), Karsten Nielsen (1, 2) (1)Department of Pathology, Naestved Hospital, (2)Institute of Regional Health Research, University of Southern Denmark. P2-6 Prostate specific antigen (PSA): Age specific reference intervals and PSA and the 5 years risk of prostate cancer. Results from a population based register study Sarah Hjartbro Bube (1), Ida Behrens (1), Lise Barthum (2,3), Karsten Nielsen (3,4) (1)Department of Urology, Naestved Hospital, (2) Department of Clinical Biochemistry, Naestved Hospital, (3)Institute of Regional Health Research, University of Southern Denmark, SDU, (4)Department of Clinical Pathology, Naestved Hospital P2-7 Renal Epithelioid Angiomyolipoma with atypia: A case report and review of the literature Marie Bjødstrup Jensen(1) Morten Andersen(2) Ulla Møldrup(2) Søren Høyer(1) (1)Department of Pathology, Aarhus University Hospital, Aarhus (2)Department of Urology, Aarhus

9 9 University Hospital, Aarhus P2-8 How to decalcify prostatectomy specimens without losing amplifiable DNA Lykke Grubach(1), Louise Serup Christoffersen(1), and Astrid Petersen (1). (1)Department of Pathology, Aalborg University Hospital. P3-1 Findings in passing stools Susanne Eiholm (1) (1)Department of Pathology, Roskilde Hospital P3-2 Why autopsies? - A ruptured abdominal aortic aneurism mimicking intra cranial haemorrhage Lenler-Eriksen, S. (1), Hager H. (1) (1)Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark. P3-3 Carcinosarcoma of the breast: a diagnostic challenge LL Jensen (1), P Vahl, V Jensen (1) (1)Department of Pathology, Aarhus University Hospital, Denmark. P3-4 Could sentinel lymph node biopsy be omitted in tubular carcinoma of the breast?-a retrospective single centre study Torshamar UEÓ, Di Caterino T (1)Department of Pathology, Hospital of South Western Jutland, Esbjerg, Denmark P3-5 A multi-disciplinary effort towards the diagnosis of Pompe disease in a young adult. An example of the muscle biopsy as an important diagnostic tool Anne R Ellingsen(1), Julie S Hansen(2), Caroline M Andreasen(3), Anne Grosen(4), Henning Andersen(2). (1)Institute of Pathology (2), Dept. of Neurology, (3) Dept. of Rheumatology and (4)Dept. of Hepatology and Gastroenterology, Aarhus University Hospital. Denmark. P3-6 Malignant lymphoma in Warthin s tumour; one tumour, two entities? Marie Fredslund Breinholt (1) (1)Department of Pathology, Roskilde Hospital. P3-7 BRAF analysis - a diagnostic tool for tall cell variant of papillary thyroid carcinoma Mette Bak Nielsen (1), Marie Louise Jespersen (1)

10 10 (1)Department of Pathology, Aarhus University Hospital P4-1 Clinical and analytical evaluation of the BD Onclarity HPV assay in women referred for colposcopy Ditte Møller Ejegod(1), Jette Junge(1), Benny Kirschner(2), Maria Franzmann(1), Carsten Rygaard(1), Maria Teresa Sandri(4), Mario Sideri(4) & Jesper Bonde(1,3). (1)Department of Pathology, (2)Department of Gynaecology, (3)Clinical Research Center, Copenhagen University Hospital, Denmark, (4) Laboratory Medicine Division, European Institute of Oncology, Milan, Italy. P4-2 HC2 versus Cobas HPV test in SurePath samples from women aged 30 years with ASCUS Fornari D(1,2), Bjerregaard B (1), Lidang M (1), Bonde J (2,3), Christensen IJ (4), Høgdall E (1) (1)Herlev University Hospital, Department of Pathology, Herlev, Denmark, (2)Hvidovre University Hospital, Department of Pathology, Hvidovre, Denmark, (3)Hvidovre University Hospital, Clinical Research Center, Hvidovre, Denmark, (4)Finsen Laboratory, Rigshospitalet, Denmark P4-3 Comparison of Genomica CLART HPV2 genotyping assay to Roche Linear Array HPV genotyping assay and Qiagen Hybrid Capture 2 Helle Pedersen(1), Ditte Møller Ejegod(1), Matejka Rebolj(3), Jette Junge(1), Maria Franzmann(1), Carsten Rygaard(1) and Jesper Bonde(1,2). (1)Department of Pathology, Copenhagen University Hospital, Hvidovre, Kettegaard Allé 30, 2650 Hvidovre, Denmark. (2)Clinical Research Center, Copenhagen University Hospital, Hvidovre, Kettegaard Allé 30, 2650 Hvidovre, Denmark. (3) University of Copenhagen, Department of Public Health, Copenhagen, Denmark. P4-4 Clinical and Analytical evaluation of the BD Onclarity HPV Assay on BD SurePath samples from women with abnormal cytology Ditte Møller Ejegod(1), Jette Junge(1), Maria Franzmann (1), Carsten Rygaard(1), Maria-Teresa Sandri(3), Mario Sideri(3) & Jesper Bonde(1,2). (1) Department of Pathology, (2) Clinical Research Center, Copenhagen University Hospital, Denmark, (3) Laboratory Medicine Division, European Institute of Oncology, Milan, Italy. P4-5 Inter and intra laboratory reproducibility of BD Onclarity HPV assay in ThinPrep primarily screening samples Ditte Møller Ejegod(1), Itziar Serrano(3), Kate S. Cuschieri(4), William A. Nussbaumer(5), Laurence M. Vaughan(5), Amar S. Ahmad(6), Jack Cuzick(6) & Jesper Bonde(1,2) (1) Department of Pathology, Copenhagen University Hospital, Hvidovre, Denmark. (2) Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark. (3) HPV Research Group, Queens Medical Research Institute, Edinburgh UK. (4) Specialist Virology centre, Royal Infirmary of Edinburgh, UK. (5) BD Diagnostics, 54 Loveton Circle, Sparks, MD 21152, USA. (6) Centre for Cancer Prevention, Wolfson Institute

11 11 of Preventive Medicine, Charterhouse Square, London, UK. P4-6 HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system Preisler S (1,2), Rebolj M (3,1,2), Ejegod D (1), Lynge E(3), Rygaard C (1), Bonde J (1,2) (1)Department of Pathology, Copenhagen University Hospital, Hvidovre, (2)Clinical Research Centre, Copenhagen University Hospital, Hvidovre, (3) Department of Public Health, University of Copenhagen P4-7 The reproducibility of the Cobas HPV Assay evaluated in a screening population of woman aged years Dorthe Ørnskov (1) Marianne Waldstrøm (1,2) (1)Department of Pathology, Vejle Hospital, Denmark (2) Institute of Regional Health Research, University of Southern Denmark. P4-8 SurePath cytology medium for HPV testing using cobas HPV test, APTIMA HPV test, HC2, BD Onclarity HPV test and CLART HPV2 genotyping assay. A joint report form the Danish HORIZON study and the Danish BD Onclarity Trial Ditte Møller Ejegod(1), Matejka Rebolj(3), Sarah Preisler(1,2), Elsebeth Lynge(3), Carsten Rygaard(1), Jesper Bonde(1,2). (1)Department of Pathology, Copenhagen University Hospital, Hvidovre, Kettegaard Allé 30, 2650 Hvidovre, Denmark. (2)Clinical Research Center, Copenhagen University Hospital, Hvidovre, Kettegaard Allé 30, 2650 Hvidovre, Denmark. (3) University of Copenhagen, Department of Public Health, Copenhagen, Denmark P5-1 Molecular HPV diagnostics and benign dermatopathology Marie Boennelycke (1), Ulla Hansen (1), Susanne Holck (1), Jesper Bonde (1,2) (1)Department of Pathology, Copenhagen University Hospital Hvidovre, Denmark, (2)Clinical Research Centre, Copenhagen University Hospital Hvidovre, Denmark P5-2 Filaggrin expression in normal tissues Kallenbach K(1), Høgdall E(1), Stender S(2), Thyssen JP(3), Johansen JD(3), Menné T(3), Carlsen BC(3), Balslev E(1), Szecsi P(2) (1)Department of Pathology, Herlev Hospital, (2)Department of Clinical Chemistry, Gentofte Hospital, (3)Department of Dermatology, Gentofte Hospital. P5-3 Merkel Cell Carcinoma concurrent with Bowen s disease and superficial basal cell carcinoma: A case report

12 12 Kiran Sheikh (1), Thomas Hasselager (1) (1)Department of Pathology, Herlev Hospital, Denmark. P5-4 Is immunohistochemistry useful in the distinction of basaloid PCC versus BCC in the anal region? Kiran Sheikh (1), Lene Buhl Riis (1) (1) Department of Pathology, Herlev Hospital P5-5 Lymphomatoid papulosis type D or an aggressive epidermotropic CD8-positive cytotoxic T-cell lymphoma the importance of clinicopathologic correlation Mathilde Skaarup Larsen(1), Rosa Marie Andersen(2), Tim Svenstrup Poulsen(1), Lone Skov(2), Anne Falensteen Lauritzen(1). (1)Department of Pathology, Copenhagen University Hospital Herlev, (2)Department of Dermato- Allergology Copenhagen University Hospital Gentofte. P5-6 Necrotic ulcer on the lower lip caused by infection with orthopoxvirus Mette Bybjerg Jensen (1) Lone Skov (2) Søren Kamp (2) Charlotte Winther (1) Signe Ledou Nielsen (1) (1)Department of Pathology, Herlev Hospital, (2)Department of Dermatology, Gentofte Hospital. P5-7 Langerhans cell histiocytosis presented as skin lesions in an adult: a case report Katrine Togsverd-Bo(1), Ann Sophie Lønnberg (2), Lone Skov (2), and Signe Ledou Nielsen (1). (1)Department of Pathology, Herlev Hospital, (2)Department of Dermatology, Gentofte Hospital P5-8 Malignant melanoma within an intradermal nevus a case report Pia Wirenfeldt Staun (1) (1)Department of Pathology, Hospital of South Western Jutland, Esbjerg, Denmark. P6-1 JAM-A - a novel prognostic marker in glioblastoma Ann Mari Rosager1,2, Rikke H. Dahlrot1-3, Steinbjørn Hansen2,3, Justin D, Lathia4, Bjarne W. Kristensen1,2 (1)Department of Pathology, Odense University Hospital, Odense, Denmark, (2)Institute of Clinical Research, University of Southern Denmark, Odense, Denmark, (3)Department of Oncology, Odense University Hospital, Odense, Denmark, (4)Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA P6-2 c-met is a new prognostic biomarker in glioblastoma patients Stine A. Petterson(1,2), Simon K. Hermansen(1,2), Rikke H. Dahlrot(1-3), Steinbjørn Hansen(2-3), Bjarne W.

13 13 Kristensen(1,2) (1)Department of Pathology, Odense University Hospital, Odense, Denmark, (2)Institute of Clinical Research, University of Southern Denmark, Odense, Denmark, (3)Department of Oncology, Odense University Hospital, Odense, Denmark P6-3 High levels of TIMP-1 can reduce the effect of topoisomerase inhibitors on glioblastoma cells Charlotte Aaberg-Jessen (1), Louise Fogh (2), Bo Halle (1, 3), Vibeke Jensen(2), Nils Brünner (2) and Bjarne Winther Kristensen (1). (1)Department of Pathology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Denmark. (2)Section of Molecular Disease Biology, Department of Veterinary Disease Biology, (3)Faculty of Health and Medical Sciences, Copenhagen. P6-4 Multi-disciplinary meetings within uro-oncology in Region Midt/Nord Jakob Kristian Jakobsen(1), Jørgen Bjerggaard Jensen(1), Søren Høyer(2) on behalf of the multidisciplinary uro-oncological group in Region Midt/Nord (1)Aarhus University Hospital, Dept. of Urology, (2)Aarhus University Hospital, Institute of Pathology. P6-5 DNA derived from PAXgene Tissue System fixed material is suitable for genome wide DNA methylation study Gitte Brinch Andersen (1), Henrik Hager (3), Lise Lotte Hansen (1), Jorg Tost (2) (1)Department of Biomedicine, Aarhus University, (3)The Bartholin Building, Wilhelm Meyers Allé 4, DK Aarhus C, Denmark, (2)Centre National de Génotypage, CEA - Institut de Génomique, Batiment G2, 2 rue Gaston Crémieux, CP5721, Evry Cedex, France P6-6 Quantification of regulatory T-cells in bone marrow biopsies from patients with Philadelphia Chromosome Negative Chronic myeloproliferative neoplasms using immunohistochemical methods Marie Fredslund Breinholt(1), Michael Bzorek(2),Signe Ledou Nielsen(1) (1)Department of Pathology, Herlev Hospital, (2) Department of Pathology, Naestved Hospital. P6-7 EBV positive diffuse large B-cell lymphoma of the elderly and preceding Angioimmunoblastic T-cell lymphoma Gitte Wooler(1), Peter Nørgaard(1)and Signe Ledou Nielsen(1). (1)Department of Pathology, Herlev Hospital, Denmark. P6-8 c-myc Expression In Newly Diagnosed Multiple Myeloma Agoston Gyula Szabo (1), Anne Ortved Gang (2), Mette Ølgod Pedersen (1), Tim Svenstrup Poulsen (1),

14 Tobias Wirenfeldt Klausen (2), and Peter H. Nørgaard (1) (1)Department of Pathology, Copenhagen University Hospital Herlev, Herlev, Denmark, (2)Department of Haematology, Copenhagen University Hospital Herlev, Herlev, Denmark. 14

10/06/2013. Commentary. The best way to achieve optimal treatment of today s patients is to ensure the availability of

10/06/2013. Commentary. The best way to achieve optimal treatment of today s patients is to ensure the availability of With main focus on the Estrogen Receptor Commentary The best way to achieve optimal treatment of today s patients is to ensure the availability of reliableand timelypathological th l i l assessment in

More information

IMO EXTERNAL RELATIONS. (b) Relations with non-governmental organizations. Note by the Secretary-General. C 98/D and C/ES.

IMO EXTERNAL RELATIONS. (b) Relations with non-governmental organizations. Note by the Secretary-General. C 98/D and C/ES. INTERNATIONAL MARITIME ORGANIZATION E IMO COUNCIL 24th extraordinary session Agenda item 12(b) C/ES.24/12(b)/1/Add.2 6 November 2007 Original: ENGLISH EXTERNAL RELATIONS (b) Relations with non-governmental

More information

HER2 Protein Expression in Breast Cancer: Membrane Morphology and Accuracy wrt. Gene Amplification

HER2 Protein Expression in Breast Cancer: Membrane Morphology and Accuracy wrt. Gene Amplification HER2 Protein Expression in Breast Cancer: Membrane Morphology and Accuracy wrt. Gene Amplification Presented by Michael Grunkin, PhD CEO & Founder of Visiopharm mgr@visiopharm.com The Breast Panel Assessment

More information

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred

More information

Sessions. Workshops. Lectures, discussions and workshops. PhD students, members of the PhD Network of Diabetes and Metabolism, Danish Diabetes Academy

Sessions. Workshops. Lectures, discussions and workshops. PhD students, members of the PhD Network of Diabetes and Metabolism, Danish Diabetes Academy Sessions PHD COURSE PROGRAMME BASAL METABOLISM AND MOLECULAR MECHANISMS IN THE METABOLIC SYNDROME I II III IV V Basal metabolism The metabolic syndrome (MS), epidemiology and fat cells Inflammation, exercise

More information

The Diagnosis of Cancer in the Pathology Laboratory

The Diagnosis of Cancer in the Pathology Laboratory The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used? Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or

More information

BRAF in the diagnostic evaluation of thyroid nodules

BRAF in the diagnostic evaluation of thyroid nodules Symposium 13 Molecular markers in thyroid cancer: current role in clinical practice BRAF in the diagnostic evaluation of thyroid nodules Laura Fugazzola University of Milan, Italy Papillary carcinoma BRAF

More information

Competitors per category

Competitors per category 11 -F-1 Competitors 1 Weightclass 1 23 Helena Brun Rasmussen Lyseng Page 1 of 43 30-09-2010 / 21:07 11 -M-2 Competitors 1 Weightclass 2 37 Thomas Purup Skanderborg Page 2 of 43 30-09-2010 / 21:07 11 -F-2

More information

GLOBAL ORGANISATIONAL STRUCTURE

GLOBAL ORGANISATIONAL STRUCTURE GLOBAL ORGANISATIONAL STRUCTURE President, CEO Sten Kjelstrup Secretary to the Management Jeanette Dyekjær President, CEO HR Sten Kjelstrup Vice President Product Development & Technical Service Henning

More information

Lif s committee/ EXPE network structure and representatives in EFPIA

Lif s committee/ EXPE network structure and representatives in EFPIA Lif s committee/ EXPE network structure and representatives in EFPIA Lif s s / EXPE Networks: EFPIA s Working Parties: Representatives: No Lif council, committee, EXPE network at the moment IPR (UIPR)

More information

Immunohistochemical differentiation of metastatic tumours

Immunohistochemical differentiation of metastatic tumours Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in

More information

GLOBAL ORGANISATIONAL STRUCTURE

GLOBAL ORGANISATIONAL STRUCTURE GLOBAL ORGANISATIONAL STRUCTURE President, CEO Sten Kjelstrup Executive, CFO Secretary to the Management Jeanette Dyekjær Product Development Henning Jørgensen Executive Vice President, CFO Global Finance,

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

Danish Lung Cancer Screening Trial (DLCST).

Danish Lung Cancer Screening Trial (DLCST). Danish Lung Cancer Screening Trial (DLCST). Röntgenveckan, Karlstad 11.september 2014 Jesper Holst Pedersen, MD, DMsci, Associate Professor Rigshospitalet University of Copenhagen, Denmark DLCST (Danish

More information

Cancer Screening. Robert L. Robinson, MD, MS. Ambulatory Conference SIU School of Medicine Department of Internal Medicine.

Cancer Screening. Robert L. Robinson, MD, MS. Ambulatory Conference SIU School of Medicine Department of Internal Medicine. Cancer Screening Robert L. Robinson, MD, MS Ambulatory Conference SIU School of Medicine Department of Internal Medicine March 13, 2003 Why screen for cancer? Early diagnosis often has a favorable prognosis

More information

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia

More information

OCCULT PRIMARY CANCER

OCCULT PRIMARY CANCER OCCULT PRIMARY CANCER พญ.ครองกมล ส หบ ณฑ หน วยมะเร งว ทยา INTRODUCTION Occult primary cancers or cancer of unknown primary (CUPS) Histologically proven metastatic malignant tumors whose primary site cannot

More information

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening. CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests

More information

The annual meeting of DSKO 2014 preliminary program Hotel Nyborg Strand, the 27 th 29 th of March 2014

The annual meeting of DSKO 2014 preliminary program Hotel Nyborg Strand, the 27 th 29 th of March 2014 The annual meeting of DSKO 2014 preliminary program Hotel Nyborg Strand, the 27 th 29 th of March 2014 Thursday 27.3.2014 15.30 16.30 Registration and coffee Hypofractionation in radiotherapy for breast

More information

GENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE

GENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE Genomics in Medicine Series GENETICS AND GENOMICS OF THYROID NEOPLASMS MOVING CLOSER TOWARDS PERSONALIZED PATIENT CARE Electron Kebebew, MD, FACS Outline To assess the change in thyroid cancer epidemiology

More information

A Genealogy Report For JOHANN FRIEDRICH BÜNGER

A Genealogy Report For JOHANN FRIEDRICH BÜNGER A Genealogy Report For JOHANN FRIEDRICH BÜNGER Created on 15 January 2011 "The Complete Genealogy Reporter" 2006-2010 Nigel Bufton Software under license to MyHeritage.com Family Tree Builder CONTENTS

More information

Danish Cardiovascular Research Academy. PhD-course: Vascular Biology and Atherothrombosis

Danish Cardiovascular Research Academy. PhD-course: Vascular Biology and Atherothrombosis Danish Cardiovascular Research Academy PhD-course: Vascular Biology and Atherothrombosis University of Aarhus, 6-10 September 2004 Aim and Content: This course will provide an overview of experimental

More information

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Outline. Workup for metastatic breast cancer. Metastatic breast cancer Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30

More information

BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner

BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome Thomas Wiesner Disclosure Listed as co-inventor US patent application US 61/463,389 BAP1 mutational analysis in determining susceptibility

More information

General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014

General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014 General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention

More information

Presentation of Energinet.dk

Presentation of Energinet.dk Presentation of Energinet.dk April 2008 1 Presentation of Energinet.dk Agenda 10:00 12:00 Welcome and presentation of Energinet.dk /Peter Jørgensen Wind integration - challenges /Antje Orths R&D in environment-friendly

More information

Fulfilling the Promise

Fulfilling the Promise Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,

More information

Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals DECEMBER 2010

Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals DECEMBER 2010 Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals DECEMBER 2010 This guide has three parts: 1. Information for health professionals 2. Tables

More information

Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid

Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid

More information

Molecular Diagnostics in Thyroid Cancer

Molecular Diagnostics in Thyroid Cancer Disclosure Nothing to disclose Jonathan George, MD, MPH Assistant Professor Head and Neck Oncologic & Endocrine Surgery Molecular Diagnostics in Thyroid Cancer Current Practices & Future Trends UCSF Medical

More information

Uterine sarcomas are very rare. They are responsible for only 1 to 5 percent of all malignancies

Uterine sarcomas are very rare. They are responsible for only 1 to 5 percent of all malignancies EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas

More information

The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.

The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers. Where does Molecular Analysis of FNA Specimens fit into the evaluation of thyroid nodules? The Role of Genetic Testing in the Evaluation of Thyroid Nodules Ultrasound TSH Risk factors Jill E. Langer, MD

More information

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj. PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

SITE VISIT SCHEDULE COPENHAGEN VETSCHOOL, 26-30 APRIL, 2015 Day/Time Activity Location Participants from Vetschool

SITE VISIT SCHEDULE COPENHAGEN VETSCHOOL, 26-30 APRIL, 2015 Day/Time Activity Location Participants from Vetschool SITE VISIT SCHEDULE COPENHAGEN VETSCHOOL, 26-30 APRIL, 2015 Day/Time Activity Location Participants from Vetschool Day 0 Saturday 25th April 2015 Arrivals to Copenhagen airport Pick up at airport and transport

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Practical Effusion Cytology

Practical Effusion Cytology Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.

More information

There are many different types of cancer and sometimes cancer is diagnosed when in fact you are not suffering from the disease at all.

There are many different types of cancer and sometimes cancer is diagnosed when in fact you are not suffering from the disease at all. About Cancer Cancer is a disease where there is a disturbance in the normal pattern of cell replacement. The cells mutate and become abnormal or grow uncontrollably. Not all tumours are cancerous (i.e.

More information

The OPUS School Meal Study New Nordic Diet for children

The OPUS School Meal Study New Nordic Diet for children The OPUS School Meal Study New Nordic Diet for children Rikke A. Petersen PhD stud rap@life.ku.dk Department of Nutrition, Exercise and Sports Background of the OPUS School Meal Study WP 7 Communication

More information

15th Colorectal Day Programme

15th Colorectal Day Programme 15th Colorectal Day Programme 7TH OF JUNE 2016 AARHUS UNIVERSITY HOSPITAL, SKEJBY ENTRANCE 6, AUDITORIUM A www.crd.auh.dk Fotograf: Kristian Bang, AUH Dear friends and colleagues It is our pleasure to

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

SITE VISIT SCHEDULE COPENHAGEN VETSCHOOL, 26-30 APRIL, 2015 Day/Time Activity Location Participants from Vetschool

SITE VISIT SCHEDULE COPENHAGEN VETSCHOOL, 26-30 APRIL, 2015 Day/Time Activity Location Participants from Vetschool SITE VISIT SCHEDULE COPENHAGEN VETSCHOOL, 26-30 APRIL, 2015 Day/Time Activity Location Participants from Vetschool Day 0 Saturday 25th April 2015 Arrivals to Copenhagen airport Pick up at airport and transport

More information

Frozen Section Diagnosis

Frozen Section Diagnosis Frozen Section Diagnosis Dr Catherine M Corbishley Honorary Consultant Histopathologist St George s Healthcare NHS Trust and lead examiner final FRCPath Practical 2008-2011 Frozen Section Diagnosis The

More information

How CanCer becomes critical in the claims

How CanCer becomes critical in the claims How CanCer becomes critical in the claims arena Cancer is a disease in which cells in your body grow in an uncontrolled way and form a lump called a tumour. In a healthy individual cells grow and reproduce

More information

YOUR LUNG CANCER PATHOLOGY REPORT

YOUR LUNG CANCER PATHOLOGY REPORT UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7

More information

Kate O Hanlan, M. D. F. A. C. O. G., F. A. C. S.

Kate O Hanlan, M. D. F. A. C. O. G., F. A. C. S. Kate O Hanlan, M. D. F. A. C. O. G., F. A. C. S. Gynecologic Oncology, Surgery and Endoscopy 4370 Alpine Road Portola Valley, CA 94028-7523 Phone: (650)-851-6669 FAX: (650) 851-9747 Regarding Ovarian Cancer,

More information

Danske Bank s organisation 2013

Danske Bank s organisation 2013 Danske Bank s organisation 2013 CEO Thomas F. Borgen Chairman of the Executive Board Personal Banking Tonny Thierry Andersen* Banking Lars Mørch* Corporates & Institutions Thomas F. Borgen* Group Risk

More information

A23: Oncologic Disease- Tumor Markers

A23: Oncologic Disease- Tumor Markers A23: Oncologic Disease- Tumor Markers Diagnosis Tumor Markers and Genetic Markers Use for Specific Malignancy The following information is from multiple guideline sources as recommendations for use of

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Early Prostate Cancer: Questions and Answers. Key Points

Early Prostate Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

Screening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group

Screening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group Screening for Cancer in Light of New Guidelines and Controversies Christopher Celio, MD St. Jude Heritage Medical Group Screening Tests The 2 major objectives of a good screening program are: (1) detection

More information

Characterisation of a Palliative Care Population in a Comprehensive Cancer Centre

Characterisation of a Palliative Care Population in a Comprehensive Cancer Centre Characterisation of a Palliative Care Population in a Comprehensive Cancer Centre Kirstine Skov Benthien, Mie Nordly, Katja Videbæk, Lisbeth Grave Bendixen, Louise Christoffersen, Hans von der Maase, Geana

More information

Cancer Screening and Early Detection Guidelines

Cancer Screening and Early Detection Guidelines Cancer Screening and Early Detection Guidelines Guillermo Tortolero Luna, MD, PhD Director Cancer Control and Population Sciences Program University of Puerto Rico Comprehensive Cancer Center ASPPR Clinical

More information

Cancer doesn t care but we do. 2010 Cancer Annual Report

Cancer doesn t care but we do. 2010 Cancer Annual Report Cancer doesn t care but we do. 2010 Cancer Annual Report The Cancer Committee of CHRISTUS St. Patrick Hospital is proud to present its 2010 Annual Report. The Community Hospital Comprehensive Cancer Program

More information

One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3

One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3 1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point

More information

Ovarian tumors Ancillary methods

Ovarian tumors Ancillary methods Ovarian tumors Ancillary methods Ovarian tumor course Oslo, 24-25/11/14 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Division of

More information

Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.

Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause. Disorders of Growth Introduction: Tumor Swelling / new growth / mass Two types of growth disorders: Non-Neoplastic Secondary / adaptation due to other cause. Neoplastic. Primary growth abnormality. Non-Neoplastic

More information

Immuno-Oncology Therapies to Treat Lung Cancer

Immuno-Oncology Therapies to Treat Lung Cancer Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own

More information

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.

Breast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D. Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are

More information

HPV OncoTect E6, E7 mrna Kit A highly specific molecular test for early detection of cervical cancer

HPV OncoTect E6, E7 mrna Kit A highly specific molecular test for early detection of cervical cancer Revolutionizing healthcare one cell at a time HPV OncoTect E6, E7 mrna Kit A highly specific molecular test for early detection of cervical cancer Numerous studies confirm that the presence of HR HPV DNA

More information

The Ontario Cancer Registry moves to the 21 st Century

The Ontario Cancer Registry moves to the 21 st Century The Ontario Cancer Registry moves to the 21 st Century Rebuilding the OCR Public Health Ontario Grand Rounds Oct. 14, 2014 Diane Nishri, MSc Mary Jane King, MPH, CTR Outline 1. What is the Ontario Cancer

More information

Common Cancers & Hereditary Syndromes

Common Cancers & Hereditary Syndromes Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.

More information

An Introduction to Cancer and Basic Cancer Vocabulary

An Introduction to Cancer and Basic Cancer Vocabulary An Introduction to Cancer and Basic Cancer Vocabulary Marc B. Garnick, MD Beth Israel Deaconess Medical Center Harvard Medical School, Boston Medical Director Cancer Programs Northeast Hospital Corporation,

More information

A 70-year old Man with Pleural Effusion

A 70-year old Man with Pleural Effusion Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which

More information

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is

More information

Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach

Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach Kerry C. Councilman, MD Assistant Professor University of Colorado Denver Goals: BRAF Mutation

More information

False positive PET in lymphoma

False positive PET in lymphoma False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)

More information

FRIEND TO FRIEND CPT CODES 2015 2016. Diagnostic digital breast tomosynthesis, unilateral (list separately in addition to code for primary procedure)

FRIEND TO FRIEND CPT CODES 2015 2016. Diagnostic digital breast tomosynthesis, unilateral (list separately in addition to code for primary procedure) FRIEND TO FRIEND CPT CODES 2015 2016 CPT CODE SERVICE DESCRIPTION FEE EFFECTIVE G0101 Screening pelvic examination $36.69 01 Jan 16 G0202 Mammography, screening, digital, bilateral (2 view film study of

More information

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

HER2 Status: What is the Difference Between Breast and Gastric Cancer? Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC

More information

Cervical Cancer The Importance of Cervical Screening and Vaccination

Cervical Cancer The Importance of Cervical Screening and Vaccination Cervical Cancer The Importance of Cervical Screening and Vaccination Cancer Cells Cancer begins in cells, the building blocks that make up tissues. Tissues make up the organs of the body. Sometimes, this

More information

Follow-Up Care for Breast Cancer

Follow-Up Care for Breast Cancer A Patient s Guide Follow-Up Care for Breast Cancer Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is a nonprofit organization which represents

More information

Cystic Neoplasms of the Pancreas: A multidisciplinary approach to the prevention and early detection of invasive pancreatic cancer.

Cystic Neoplasms of the Pancreas: A multidisciplinary approach to the prevention and early detection of invasive pancreatic cancer. This lecture is drawn from the continuing medical education program Finding Hope: Prevention, Early Detection and Treatment of Pancreatic Cancer, Nov, 2011. Robert P. Jury, MD Cystic Neoplasms of the Pancreas:

More information

Application of Molecular Diagnosis: Present and Future

Application of Molecular Diagnosis: Present and Future Application of Molecular Diagnosis: Present and Future Dong Jun Lim, MD., PhD. Associate Professor Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary s Hospital,

More information

Update on Mesothelioma

Update on Mesothelioma November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

More information

Progress and Prospects in Ovarian Cancer Screening and Prevention

Progress and Prospects in Ovarian Cancer Screening and Prevention Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian

More information

1. What is the prostate-specific antigen (PSA) test?

1. What is the prostate-specific antigen (PSA) test? 1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor

More information

Hosts. New Methods for Treating Colorectal Cancer

Hosts. New Methods for Treating Colorectal Cancer Hosts Anees Chagpar MD Associate Professor of Surgical Oncology Francine MD Professor of Medical Oncology New Methods for Treating Colorectal Cancer Guest Expert: Scott, MD Associate Professor in the Department

More information

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma

More information

Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach

Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach Publishing Team Erik Tanck (production manager/designer) Joshua Weikersheimer (publisher) Copyright 2006 by the American Society

More information

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal

More information

New strategies in anticancer therapy

New strategies in anticancer therapy 癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive

More information

Colorectal Cancer Care A Cancer Care Map for Patients

Colorectal Cancer Care A Cancer Care Map for Patients Colorectal Cancer Care A Cancer Care Map for Patients Understanding the process of care that a patient goes through in the diagnosis and treatment of colorectal cancer in BC. Colorectal Cancer Care Map

More information

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,

More information

Issued: September 2013. NICE diagnostics guidance 10. www.nice.org.uk/dg10

Issued: September 2013. NICE diagnostics guidance 10. www.nice.org.uk/dg10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September

More information

Conflict of Interest. Overdiagnosis. Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates 4/17/2015. Jeffrey F.

Conflict of Interest. Overdiagnosis. Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates 4/17/2015. Jeffrey F. Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates Jeffrey F. Krane, MD PhD Associate Professor of Pathology Harvard Medical School Chief, Head and Neck Pathology Service Associate Director,

More information

Pathology of lung cancer

Pathology of lung cancer Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu

More information

Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare

Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare Maria Chiara Zatelli Sezione di Endocrinologia Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università

More information

Ki-1 Large Cell Anaplastic Lymphoma - A Clinicopathological Study

Ki-1 Large Cell Anaplastic Lymphoma - A Clinicopathological Study Ki-1 Large Cell Anaplastic Lymphoma - A Clinicopathological Study Pages with reference to book, From 169 To 171 Sajid Mushtaq, Iftikhar A. Malik, Manzoor Ahmed, M. Safdar Khan, Amir Hussain Khan, Shahid

More information

Diagnosis and Treatment of Common Oral Lesions Causing Pain

Diagnosis and Treatment of Common Oral Lesions Causing Pain Diagnosis and Treatment of Common Oral Lesions Causing Pain John D. McDowell, DDS, MS University of Colorado School of Dentistry Chair, Oral Diagnosis, Medicine and Radiology Director, Oral Medicine and

More information

HVEM ER HVEM. Dansk Dagligvarehandel. august 2014

HVEM ER HVEM. Dansk Dagligvarehandel. august 2014 HVEM ER HVEM Dansk Dagligvarehandel august 2014 HVEM ER HVEM DANSK SUPERMARKED Commercial Management Commercial Categories Bilka Føtex Netto Salling Commercial Viktor Jegesi Ole Andersen CEO Commercial

More information

Cancer in Ireland 2013: Annual report of the National Cancer Registry

Cancer in Ireland 2013: Annual report of the National Cancer Registry Cancer in 2013: Annual report of the National Cancer Registry ABBREVIATIONS Acronyms 95% CI 95% confidence interval APC Annual percentage change ASR Age standardised rate (European standard population)

More information

Policy Wording. Together, all the way.

Policy Wording. Together, all the way. Cancer cover Policy Wording Together, all the way. Cancer Cover Insurance Policy Wording 1. Introducing your Policy 2. What is Cancer Cover Insurance? 3. About your Policy 4. Some terms defined 5. What

More information

THEMATIC REVIEW ON ADULT LEARNING

THEMATIC REVIEW ON ADULT LEARNING THEMATIC REVIEW ON ADULT LEARNING DENMARK Visit of 7-14 November 2000 PROGRAMME AND PARTICIPANTS Monday 6 November Copenhagen Location: Uddannelsesstyrelsen (Education Authority) 15:00-17:00 Meeting with

More information

NICE guideline Published: 23 June 2015 nice.org.uk/guidance/ng12

NICE guideline Published: 23 June 2015 nice.org.uk/guidance/ng12 Suspected : recognition and referral NICE guideline Published: 23 June 2015 nice.org.uk/guidance/ng12 NICE 2015. All rights reserved. Contents Introduction... 5 Safeguarding children... 6 Patient-centred

More information

BREAST CANCER PATHOLOGY

BREAST CANCER PATHOLOGY BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know

More information